Selected Publications
Luo J, Sanchez M, Lee E, Hertzler H, Luong N, Mazzola E, Finstein B, Tamen R, Brisbane G, Nguyen T, Paik PK, Chaft JE, Cheng ML, Khalil H, Piha-Paul SA, Sholl LM, Nishino M, Jänne PA, DuBois SG, Hanna GJ, Shapiro GI, French CA. Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma. J Thorac Oncol. 2023 Dec 27:S1556-0864(23)02431-0. doi: 10.1016/j.jtho.2023.12.022. Epub ahead of print. PMID: 38154515. [pdf]
Durall RT, Huang J, Wojenski L, Huang Y, Gokhale PC, Leeper BA, Nash JO, Ballester PL, Davidson S, Shlien A, Sotirakis E, Bertaux F, Dubus V, Luo J, Wu CJ, Keskin DB, Eagen KP, Shapiro GI, French CA. The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma. Cancer Res. 2023 Dec 1;83(23):3846-3860. doi: 10.1158/0008-5472.CAN-23-2545. PMID: 37819236; PMCID: PMC10690098.
Huang Y, Durall RT, Luong NM, Hertzler HJ, Huang J, Gokhale PC, Leeper BA, Persky NS, Root DE, Anekal PV, Montero Llopis PDLM, David CN, Kutok JL, Raimondi A, Saluja K, Luo J, Zahnow CA, Adane B, Stegmaier K, Hawkins CE, Ponne C, Le Q, Shapiro GI, Lemieux ME, Eagen KP, French CA. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Res. 2023 Dec 1;83(23):3956-3973. doi: 10.1158/0008-5472.CAN-23-1475. PMID: 37747726; PMCID: PMC10843040.
Barletta JA, Gilday SD, Afkhami M, Bell D, Bocklage T, Boisselier P, Chau NG, Cipriani NA, Costes-Martineau V, Ghossein RA, Hertzler HJ, Kramer AM, Limaye S, Lopez CA, Ng TL, Weissferdt A, Xu B, Zhang S, French CA. NUTM1 -rearranged Carcinoma of the Thyroid : A Distinct Subset of NUT Carcinoma Characterized by Frequent NSD3 – NUTM1 Fusions. Am J Surg Pathol. 2022 Dec 1;46(12):1706-1715. doi: 10.1097/PAS.0000000000001967. Epub 2022 Aug 29. PMID: 36040068; PMCID: PMC9669222.
French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI. Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 Jun 13;28(12):2493-2505. doi: 10.1158/1078-0432.CCR-22-0591. PMID: 35417004; PMCID: PMC9197941.
Morrison-Smith CD, Knox TM, Filic I, Soroko KM, Eschle BK, Wilkens MK, Gokhale PC, Giles F, Griffin A, Brown B, Shapiro GI, Zucconi BE, Cole PA, Lemieux ME, French CA. Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734. Mol Cancer Ther. 2020 May 5:molcanther.0087.2020. doi: 10.1158/1535-7163.MCT-20-0087. PMID: 32371576. [link]
Piha-Paul SA, Hann CL, French CA, Cousin S, Braña I, Cassier PA, Moreno V, de Bono JS, Harward SD, Ferron-Brady G, Barbash O, Wyce A, Wu Y, Horner T, Annan M, Parr NJ, Prinjha RK, Carpenter CL, Hilton J, Hong DS, Haas NB, Markowski MC, Dhar A, O’Dwyer PJ, Shapiro GI. Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectr. 2019 Nov 6;4(2):pkz093. doi: 10.1093/jncics/pkz093. PMID: 32328561; PMCID: PMC7165800
Chau NG, Ma C, Danga K, Al-Sayegh H, Sridharan M, Nardi V, Barrette R, Lathan C, DuBois SG, Haddad RI, Shapiro G, Sallan SE, Dhar A, Nelson JJ, French CA. An anatomical site and genetic based prognostic model for patients with NUT midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr. 2019 Nov 6;4(2):pkz094. doi: 10.1093/jncics/pkz094. PMID: 32328562; PMCID: PMC7165803
Alekseyenko AA, Walsh EM, Zee BM, Pakozdi T, Hsi P, Lemieux ME, Dal Cin P, Ince TA, Kharchenko PV, Kuroda MI, French CA. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. Proc Natl Acad Sci 2017 May 23;114(21):E4184-E4192. [pdf]
Chau N.G., Hurwitz S., Mitchell C.M., Aserlind A., Grunfeld N., Kaplan L., Hsi P., Bauer D.E., Lathan C.S., Rodriguez-Galindo C., Tishler R.B., Haddad R.I., Sallan S.E., Bradner J.E., French C.A. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer 2016 Dec 1;122(23):3632-3640. [pdf]
Stathis A., Zucca E., Bekradda M., Gomez-Roca C., Delord J.P., de La Motte Rouge T., Uro-Coste E., de Braud F., Pelosi G., French C.A. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discov. 2016 May;6(5):492-500. [pdf]
Alekseyenko A.A., Walsh E.M., Wang X., Grayson A.R., Hsi P.T., Kharchenko P.V., Kuroda M.I., French C.A. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev. 2015 Jul 15;29(14):1507-23. [pdf]
Chau N.G., Mitchell C.M., Aserlind A., Grunfeld N., Kaplan L., Bauer D.E., Lathan C.S., Rodriguez-Galindo C., Hurwitz S., Tishler R.B., Haddad R.I., Sallan S.E., Bradner J.E., French C.A. Aggressive treatment and survival outcomes in NUT midline carcinoma (NMC) of the head and neck (HN). Journal of Clinical Oncology. 2014 ASCO Annual Meeting Abstracts. May 20 Supplement 32 (No 15_suppl): 6057. [pdf]
French C.A., Rahman S., Walsh E.M., Kühnle S., Grayson A.R., Lemieux M.E., Grunfeld N., Rubin B.P., Antonescu C.R., Zhang S., Venkatramani R., Dal Cin P., Howley P.M. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov. 2014 Aug;4(8):928-41. [pdf]
Bauer D.E., Mitchell C.M., Strait K.M., Lathan C.S., Stelow E.B., Lüer S.C., Muhammed S., Evans A.G., Sholl L.M., Rosai J., Giraldi E., Oakley R.P., Rodriguez-Galindo C., London W.B., Sallan S.E., Bradner J.E., French C.A. Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. Clin Cancer Res. 2012 Oct 15;18(20):5773-9. [pdf]
French, C.A. Pathogenesis of NUT Midline Carcinoma. Annu Rev Pathol. 2012;7:247-65. [pdf]
Schwartz, B.E., Hofer, M.D., Lemieux, M.E., Bauer, D.E., Cameron, M.J., West, N.H., Agoston, E.S., Reynoird, N., Khochbin, S., Ince, T.A., Christie, A., Janeway, K.A., Vargas, S.O., Perez-Atayde, A.R., Aster, J.C., Sallan, S.E., Kung, A.L., Bradner, J.E., French, C.A. Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming. Cancer Res. 2011 Apr 1;71(7):2686-96. [pdf]
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse, E.M., Keates, T., Hickman, T.T., Felletar, I., Philpott, M., Munro, S., McKeown, M.R., Wang, Y., Christie, A.L., West, N., Cameron, M.J., Schwartz, B., Heightman, T.D., La Thangue, N., French, C.A., Wiest, O., Kung, A.L., Knapp, S., Bradner, J.E. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. [pdf]
Reynoird, N., Schwartz, B.E., Delvecchio, M., Sadoul, K., Meyers, D., Mukherjee, C., Caron, C., Kimura, H., Rousseaux, S., Cole, P.A., et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010 Sep 1;29(17):2943-52. [pdf]
French, C.A. Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol. 2010 Jun;63(6):492-6.
Haack H, Johnson LA, Fry CJ, Crosby K, Polakiewicz RD, Stelow EB, Seung-Mo Hong, Schwartz BE, Cameron MJ, Rubin MA, Chang MC, Aster JC, French CA. Diagnosis of NUT Midline Carcinoma Using a NUT-Specific Monoclonal Antibody. Am J Surg Pathol. 2009 Jul;33(7):984-91. [pdf]
Stelow, E.B., Bellizzi, A.M., Taneja, K., Mills, S.E., Legallo, R.D., Kutok, J.L., Aster, J.C., and French, C.A. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008 Jun;32(6):828-34.
French, C.A., Ramirez, C.L., Kolmakova, J., Hickman, T.T., Cameron, M.J., Thyne, M.E., Kutok, J.L., Toretsky, J.A., Tadavarthy, A.K., Kees, U.R., et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008 Apr 3;27(15):2237-42. [pdf]
Jang, M.K., Mochizuki, K., Zhou, M., Jeong, H.S., Brady, J.N., and Ozato, K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005 Aug 19;19(4):523-34.
French, C.A., Miyoshi, I., Kubonishi, I., Grier, H.E., Perez-Atayde, A.R., and Fletcher, J.A. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003 Jan 15;63(2):304-7. [pdf]
Yang, Z., Yik, J.H., Chen, R., He, N., Jang, M.K., Ozato, K., and Zhou, Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005 Aug 19;19(4):535-45.
Dey, A., Ellenberg, J., Farina, A., Coleman, A.E., Maruyama, T., Sciortino, S., Lippincott-Schwartz, J., and Ozato, K. A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition. Mol Cell Biol. 2000 Sep;20(17):6537-49.